From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2020 Sep 15

PMID 32928087

Citations 3

Authors

Jazmin Alarcon-Esposito

Michael Mallea

Julio Rodriguez-Lavado

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a chronic, progressive, and fatal neurodegenerative disorder affecting cognition, behavior, and function, being one of the most common causes of mental deterioration in elderly people. Once thought as being just developed because of β amyloid depositions or neurofibrillary Tau tangles, during the last decades, numerous AD-related targets have been established, the multifactorial nature of AD became evident. In this context, the one drug-one target paradigm has resulted in being inefficient in facing AD and other disorders with complex etiology, opening the field for the emergence of the multitarget approach. In this review, we highlight the recent advances within this area, emphasizing in hybridization tools of well-known chemical scaffolds endowed with pharmacological properties concerning AD, such as curcumin-, resveratrol-, chromone- and indole-. We focus mainly on well established and incipient AD therapeutic targets, AChE, BuChE, MAOs, β-amyloid deposition, 5-HT4 and Serotonin transporter, with the aim to shed light about new insights in the AD multitarget therapy.

Citing Articles

Recent Advances in the Search for Effective Anti-Alzheimer's Drugs.

Ogos M, Stary D, Bajda M Int J Mol Sci. 2025; 26(1.

PMID: 39796014 PMC: 11720639. DOI: 10.3390/ijms26010157.

Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.

Cacabelos R, Martinez-Iglesias O, Cacabelos N, Carrera I, Corzo L, Naidoo V Life (Basel). 2025; 14(12.

PMID: 39768263 PMC: 11678002. DOI: 10.3390/life14121555.

Efficient synthesis of 1,2-disubstituted benzimidazoles catalyzed by phosphoric acid as a homogeneous catalyst under mild conditions and investigating their anti-diabetes properties through molecular docking studies and calculations.

Moazeni Bistgani A, Dehghani A, Moradi L RSC Adv. 2023; 13(51):35781-35790.

PMID: 38074406 PMC: 10706800. DOI: 10.1039/d3ra07156a.

Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis.

Sampietro A, Perez-Areales F, Martinez P, Arce E, Galdeano C, Munoz-Torrero D Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631371 PMC: 9146451. DOI: 10.3390/ph15050545.

Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.

Rossi M, Freschi M, de Camargo Nascente L, Salerno A, de Melo Viana Teixeira S, Nachon F J Med Chem. 2021; 64(8):4972-4990.

PMID: 33829779 PMC: 8154578. DOI: 10.1021/acs.jmedchem.1c00048.

References

Bisht K, Sharma K, Tremblay M . Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiol Stress. 2018; 9:9-21. PMC: 6035903. DOI: 10.1016/j.ynstr.2018.05.003. View

Jakob-Roetne R, Jacobsen H . Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl. 2009; 48(17):3030-59. DOI: 10.1002/anie.200802808. View

Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H . Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015; 36(5):297-309. DOI: 10.1016/j.tips.2015.03.002. View

Teskac K, Kristl J . The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2009; 390(1):61-9. DOI: 10.1016/j.ijpharm.2009.10.011. View

Al-Edresi S, Alsalahat I, Freeman S, Aojula H, Penny J . Resveratrol-mediated cleavage of amyloid β peptide: potential relevance to Alzheimer's disease. Neurobiol Aging. 2020; 94:24-33. DOI: 10.1016/j.neurobiolaging.2020.04.012. View

Domling A, Wang W, Wang K . Chemistry and biology of multicomponent reactions. Chem Rev. 2012; 112(6):3083-135. PMC: 3712876. DOI: 10.1021/cr100233r. View

Li F, Wu J, Wang J, Yang X, Cai P, Liu Q . Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease. Bioorg Med Chem. 2017; 25(14):3815-3826. DOI: 10.1016/j.bmc.2017.05.027. View

Gong C, Grundke-Iqbal I, Iqbal K . Targeting tau protein in Alzheimer's disease. Drugs Aging. 2010; 27(5):351-65. DOI: 10.2165/11536110-000000000-00000. View

Dingwall C . Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J Clin Invest. 2001; 108(9):1243-6. PMC: 209454. DOI: 10.1172/JCI14402. View

10.

Oliveira C, Bagetta D, Cagide F, Teixeira J, Amorim R, Silva T . Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. Eur J Med Chem. 2019; 174:116-129. DOI: 10.1016/j.ejmech.2019.04.026. View

11.

Jeandet P, Sobarzo-Sanchez E, Sanches Silva A, Clement C, Nabavi S, Battino M . Whole-cell biocatalytic, enzymatic and green chemistry methods for the production of resveratrol and its derivatives. Biotechnol Adv. 2019; 39:107461. DOI: 10.1016/j.biotechadv.2019.107461. View

12.

Pulina M, Hopkins M, Haroutunian V, Greengard P, Bustos V . C99 selectively accumulates in vulnerable neurons in Alzheimer's disease. Alzheimers Dement. 2019; 16(2):273-282. DOI: 10.1016/j.jalz.2019.09.002. View

13.

Elgazwy A, Edrees M, Ismail N . Molecular modeling study bioactive natural product of khellin analogues as a novel potential pharmacophore of EGFR inhibitors. J Enzyme Inhib Med Chem. 2012; 28(6):1171-81. DOI: 10.3109/14756366.2012.719504. View

14.

Ricciarelli R, Fedele E . The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. Curr Neuropharmacol. 2017; 15(6):926-935. PMC: 5652035. DOI: 10.2174/1570159X15666170116143743. View

15.

Baum L, Ng A . Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis. 2004; 6(4):367-77. DOI: 10.3233/jad-2004-6403. View

16.

Bush A, Tanzi R . Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 2008; 5(3):421-32. PMC: 2518205. DOI: 10.1016/j.nurt.2008.05.001. View

17.

Ambree O, Richter H, Sachser N, Lewejohann L, Dere E, De Souza Silva M . Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging. 2007; 30(8):1192-204. DOI: 10.1016/j.neurobiolaging.2007.11.010. View

18.

Stevens C, Hanna Jr J, Lammi R . Synthesis of tetrahydroxybiphenyls and tetrahydroxyterphenyls and their evaluation as amyloid-β aggregation inhibitors. Bioorg Med Chem Lett. 2013; 23(6):1703-6. PMC: 3594554. DOI: 10.1016/j.bmcl.2013.01.076. View

19.

Lorke D, Lu G, Cho E, Yew D . Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006; 7:36. PMC: 1523198. DOI: 10.1186/1471-2202-7-36. View

20.

Alves F, Barreiro E, Fraga C . From nature to drug discovery: the indole scaffold as a 'privileged structure'. Mini Rev Med Chem. 2009; 9(7):782-93. DOI: 10.2174/138955709788452649. View